These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 28342135)
1. PACAP Protects Against Ethanol and Nicotine Toxicity in SH-SY5Y Cells: Implications for Drinking-Smoking Co-morbidity. Manavalan S; Getachew B; Manaye KF; Khundmiri SJ; Csoka AB; McKinley R; Tamas A; Reglodi D; Tizabi Y Neurotox Res; 2017 Jul; 32(1):8-13. PubMed ID: 28342135 [TBL] [Abstract][Full Text] [Related]
2. Toxic effects of low alcohol and nicotine combinations in SH-SY5Y cells are apoptotically mediated. Ramlochansingh C; Taylor RE; Tizabi Y Neurotox Res; 2011 Oct; 20(3):263-9. PubMed ID: 21222065 [TBL] [Abstract][Full Text] [Related]
3. PACAP protects against salsolinol-induced toxicity in dopaminergic SH-SY5Y cells: implication for Parkinson's disease. Brown D; Tamas A; Reglödi D; Tizabi Y J Mol Neurosci; 2013 Jul; 50(3):600-7. PubMed ID: 23625270 [TBL] [Abstract][Full Text] [Related]
4. Characterization of novel splice variants of the PAC1 receptor in human neuroblastoma cells: consequences for signaling by VIP and PACAP. Lutz EM; Ronaldson E; Shaw P; Johnson MS; Holland PJ; Mitchell R Mol Cell Neurosci; 2006 Feb; 31(2):193-209. PubMed ID: 16226889 [TBL] [Abstract][Full Text] [Related]
5. Maxadilan interacts with receptors for pituitary adenylyl cyclase activating peptide in human SH-SY5Y and SK-N-MC neuroblastoma cells. Eggenberger M; Born W; Zimmermann U; Lerner EA; Fischer JA; Muff R Neuropeptides; 1999 Apr; 33(2):107-14. PubMed ID: 10657479 [TBL] [Abstract][Full Text] [Related]
6. PACAP protects against inflammatory-mediated toxicity in dopaminergic SH-SY5Y cells: implication for Parkinson's disease. Brown D; Tamas A; Reglodi D; Tizabi Y Neurotox Res; 2014 Oct; 26(3):230-9. PubMed ID: 24740430 [TBL] [Abstract][Full Text] [Related]
7. Pituitary adenylate cyclase-activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death. Vaudry D; Rousselle C; Basille M; Falluel-Morel A; Pamantung TF; Fontaine M; Fournier A; Vaudry H; Gonzalez BJ Proc Natl Acad Sci U S A; 2002 Apr; 99(9):6398-403. PubMed ID: 11972030 [TBL] [Abstract][Full Text] [Related]
8. Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs. Rawlings SR; Piuz I; Schlegel W; Bockaert J; Journot L Endocrinology; 1995 May; 136(5):2088-98. PubMed ID: 7720658 [TBL] [Abstract][Full Text] [Related]
9. Enhanced cAMP production mediates the stimulatory action of pituitary adenylate cyclase activating polypeptide (PACAP) on in vitro catecholamine secretion from bovine adrenal chromaffin cells. Perrin D; Germeshausen A; Söling HD; Wuttke W; Jarry H Exp Clin Endocrinol Diabetes; 1995; 103(2):81-7. PubMed ID: 7553079 [TBL] [Abstract][Full Text] [Related]
10. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes. Akesson L; Ahrén B; Edgren G; Degerman E Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088 [TBL] [Abstract][Full Text] [Related]
11. Additive protective effects of donepezil and nicotine against salsolinol-induced cytotoxicity in SH-SY5Y cells. Das JR; Tizabi Y Neurotox Res; 2009 Oct; 16(3):194-204. PubMed ID: 19526284 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of PACAP in alcohol toxicity. Reglodi D; Toth D; Vicena V; Manavalan S; Brown D; Getachew B; Tizabi Y Neurochem Int; 2019 Mar; 124():238-244. PubMed ID: 30682380 [TBL] [Abstract][Full Text] [Related]
13. PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor. Jansen-Olesen I; Baun M; Amrutkar DV; Ramachandran R; Christophersen DV; Olesen J Neuropeptides; 2014 Apr; 48(2):53-64. PubMed ID: 24508136 [TBL] [Abstract][Full Text] [Related]
14. Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced in vivo cardiovascular side effects in a Parkinson's disease model. Lamine A; Létourneau M; Doan ND; Maucotel J; Couvineau A; Vaudry H; Chatenet D; Vaudry D; Fournier A Neuropharmacology; 2016 Sep; 108():440-50. PubMed ID: 26006268 [TBL] [Abstract][Full Text] [Related]
16. Pleiotropic functions of PACAP in the CNS: neuroprotection and neurodevelopment. Shioda S; Ohtaki H; Nakamachi T; Dohi K; Watanabe J; Nakajo S; Arata S; Kitamura S; Okuda H; Takenoya F; Kitamura Y Ann N Y Acad Sci; 2006 Jul; 1070():550-60. PubMed ID: 16888224 [TBL] [Abstract][Full Text] [Related]
17. Neurotrophic actions of PACAP-38 and LIF on human neuroblastoma SH-SY5Y cells. Monaghan TK; Pou C; MacKenzie CJ; Plevin R; Lutz EM J Mol Neurosci; 2008 Nov; 36(1-3):45-56. PubMed ID: 18506635 [TBL] [Abstract][Full Text] [Related]
18. Regulation of growth hormone release in common carp pituitary cells by pituitary adenylate cyclase-activating polypeptide: signal transduction involves cAMP- and calcium-dependent mechanisms. Xiao D; Chu MM; Lee EK; Lin HR; Wong AO Neuroendocrinology; 2002 Nov; 76(5):325-38. PubMed ID: 12457043 [TBL] [Abstract][Full Text] [Related]
19. Pituitary adenylate cyclase activating polypeptide and PAC1 receptor signaling increase Homer 1a expression in central and peripheral neurons. Girard BM; Keller ET; Schutz KC; May V; Braas KM Regul Pept; 2004 Dec; 123(1-3):107-16. PubMed ID: 15518900 [TBL] [Abstract][Full Text] [Related]
20. [Pituitary adenylate cyclase activating polypeptide protects neuro-2a cells from beta amyloid protein cytotoxicity by modulating intracellular calcium]. Gui LR; Zhou Y; Zhang BL; Li WB Sheng Li Xue Bao; 2003 Feb; 55(1):42-6. PubMed ID: 12598933 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]